Table 2.
Adverse events that occurred with an incidence of ≥20% and serious adverse events that occurred in more than one patient for participants of the High Dose Discontinuation Azacitidine+Venetoclax (HiDDAV) Study.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.